Neuropsychiatric symptoms in dementia and the effects of ginkgo biloba extract egb 761® treatment: Additional results from a 24-week randomized, placebo-controlled trial

Open Access Journal of Clinical Trials

Volumn 8, Issue , 2016, Pages

  Nacu, Anatol ^a   Hoerr, Robert ^b  

^a STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Dementia; EGb 761 ; Ginkgo biloba; Neuropsychiatric symptoms; Randomized controlled trial

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ADULT; AGED; ANXIETY; APATHY; ARTICLE; CAREGIVER; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GINKGO BILOBA; HUMAN; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPSYCHIATRIC INVENTORY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT SATISFACTION; PERFORMANCE; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDER; VISUAL ANALOG SCALE;

EID: 85011983845     PISSN: None     EISSN: 11791519     Source Type: Journal    
DOI: 10.2147/OAJCT.S93531     Document Type: Article

References (22)

1. Cummings JL, McPherson S. Neuropsychiatric assessment of Alzheimer’s disease and related dementias. Aging Clinical and Experimental Research. 2001;13(3):240–246.
2. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–1483.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–944.
4. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
6. Ihl R, Frölich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease. World J Biol Psychiatry. 2011;12(1):2–32.
7. Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and metaanalysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065–2077.
8. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46(6):716–723.
9. ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Good Clinical Practice: Consolidated Guideline. ICH Topic E6-Step 5. Geneva: ICH; 1996. Available from: http://www.ich.org/fileadmin/Public_Web_ Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed December 18, 2015.
10. Mahoney R, Johnston K, Katona C, Maxmin K, Livingston G. The TE4D-Cog: a new test for detecting early dementia in English-speaking populations. Int J Geriatr Psychiatry. 2005;20(12):1172–1179.
11. KimYS, Nibbelink DW, Overall JE. Factor structure and scoring of the SKT test battery. J Clin Psychol. 1993;49(1):61–71.
12. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–S16.
13. Scripnikov A, Khomenko A, Napryeyenko O; GINDEM-NP Study Group. Effects of Ginkgo biloba extract EGb 761® on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157(13–14):295–300.
14. Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209–215.
15. Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): Effects of EGb 761®. Pharmacopsychiatry. 2003;36 Suppl 1: S56–S61.
16. Halama P, Bartsch G, Meng G. Hirnleistungsstörungen vaskulärer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Ginkgo-biloba-Extrakt [Cerebrovascular insufficiency – Placebocontrolled, randomized, doubleblind trial on the effect of Ginkgo biloba extract]. Fortschr Med. 1988;106(19):408–412. German.
17. Mjørud M, Røsvik J, Rokstad, Kirkevold M, Engedal K. Variables associated with change in quality of life among persons with dementia in nursing homes: a 10 months follow-up study. PLoS One. 2014;9(12):e115248.
18. Santos RL, Sousa MF, Simões-Neto JP, et al. Caregivers’ quality of life in mild and moderate dementia. Arq Neuropsiquiatr. 2014;72(12): 931–937.
19. Okura T, Langa KM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis Assoc Disord. 2011;25(2):116–121.
20. Rabins PV, Schwartz S, Black BS, et al. Predictors of progression to severe Alzheimer’s disease in an incidence sample. Alzheimers Dement. 2013;9(2):204–207.
21. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–177.
22. Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry. 2006;14(5):438–445.